Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,323 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No medication Clear all
Terminated Phase 1 Interventional

Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

NCT02508441
View directory record Official record
Conditions
Advanced Unresectable Solid Tumors
Interventions
Andes-1537 for Injection
Drug
Lead sponsor
Andes Biotechnologies
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Phase 2 Interventional Results available

Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia

NCT04139018
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Timolol Gel, Placebo Gel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 15, 2026, 12:41 AM EDT
Completed No phase listed Observational

Urine Proteome of Surgical Patients and Healthy Volunteers

NCT01538823
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 15, 2026, 12:41 AM EDT
Terminated Not applicable Interventional

A Pilot Study To Assess Guidance in and Subsequent Use of Mind-Body Techniques on the Quality of Life of Cancer Patients

NCT01586546
View directory record Official record
Conditions
Quality of Life, Life Change Events, Neoplasms
Interventions
Face-to-Face MBM Skills Group, Waitlist Control I, Waitlist Control II, Online MBM Skills Group
Behavioral · Other
Lead sponsor
Absenger Cancer Education Foundation
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Spring Lake, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 15, 2026, 12:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Linking Individuals Needing Care for Substance Use Disorders to Peer Coaches & Across INcarceration Settings

NCT07563517
View directory record Official record
Conditions
Substance Use
Interventions
Virtual Peer Recovery Coaching, Treatment as Usual
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 15, 2026, 12:41 AM EDT
Active, not recruiting No phase listed Observational

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

NCT03428646
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
93
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer

NCT00525590
View directory record Official record
Conditions
Metastatic Brain Cancer
Interventions
GLIADEL
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 15, 2026, 12:41 AM EDT
Not yet recruiting Not applicable Interventional

Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief

NCT07501676
View directory record Official record
Conditions
Postoperative Pain After Uterine Fibroid Embolization, Uterine Fibroids (UF), Uterine Fibroids, Pelvic Pain, Pain Management
Interventions
TUNES (Transmucosal Uterosacral Electrical Stimulation), Sham TUNES Device
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
28 Years to 52 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

NCT00569868
View directory record Official record
Conditions
MULTIPLE MYELOMA
Interventions
Velcade
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 15, 2026, 12:41 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

NCT04028960
View directory record Official record
Conditions
Type1diabetes
Interventions
Regular insulin (Humulin-R), intranasal route, SipNose intranasal device
Drug · Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Phase 4 Interventional Results available

Preoperative Steroids in Autoimmune Thyroid Disease

NCT04542278
View directory record Official record
Conditions
Thyroid Diseases
Interventions
Prednisone
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 15, 2026, 12:41 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)

NCT00951743
View directory record Official record
Conditions
HIV Infections
Interventions
Adaptavir (monomeric DAPTA)
Drug
Lead sponsor
Rapid Laboratories Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2009 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Phase 2 Interventional Results available

Stress and Medication Effects on Cocaine Cue Reactivity

NCT00613015
View directory record Official record
Conditions
Cocaine Related Disorders
Interventions
Guanfacine, Modafinil, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 15, 2026, 12:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Uncovering the 'ORIGINS' of Diabetes

NCT02226640
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Automating Peer Learning to Reduce Alcohol Use and Related Deviant Behavior in Secondary School

NCT04478240
View directory record Official record
Conditions
Substance Use, Stress, Relation, Interpersonal, Bullying, Victimisation, Mental Health Issue, Sleep, Inadequate, Social Skills
Interventions
PeerLearning.net
Behavioral
Lead sponsor
Oregon Research Behavioral Intervention Strategies, Inc.
Industry
Eligibility
Not listed
Enrollment
924 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Phase 3 Interventional

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT04368559
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions
Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 12:41 AM EDT
Terminated Not applicable Interventional Results available

Trauma Study: Early Warning of Progression Toward Hemodynamic Deterioration After Trauma

NCT04912232
View directory record Official record
Conditions
Occult Bleeding, Hemorrhage
Interventions
Detection of Occult Hemorrhage in Trauma Patients
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 15, 2026, 12:41 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

NCT06284460
View directory record Official record
Conditions
Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm
Interventions
ASTX029, ASTX727
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Not applicable Interventional Results available

Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)

NCT01616082
View directory record Official record
Conditions
Obesity, Overweight, Metabolic Diseases
Interventions
Low Calorie Diet (LCD), Phentermine
Behavioral · Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 15, 2026, 12:41 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Event-Related Potential (ERP) Components in Clinical Diagnosis

NCT05673759
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
Interventions
Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests
Device · Behavioral
Lead sponsor
Boston University
Other
Eligibility
20 Years to 90 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 15, 2026, 12:41 AM EDT
Recruiting Not applicable Interventional

Platform of Randomized Adaptive Clinical Trials in Critical Illness

NCT05440851
View directory record Official record
Conditions
Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
Interventions
Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
Other · Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

NCT04663737
View directory record Official record
Conditions
Covid19
Interventions
Silmitasertib, SOC
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

NCT02210780
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 15, 2026, 12:41 AM EDT
Completed Not applicable Interventional Results available

Smoking Cessation Using Motivational Therapy and Varenicline

NCT00701896
View directory record Official record
Conditions
Smoking, HIV Infections
Interventions
Varenicline tartrate, Nicotine Replacement Therapy, Biological Control, Motivational Interview
Drug · Other · Behavioral
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 15, 2026, 12:41 AM EDT